Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

Chen, W. ; Bjermer, L. LU and Price, D.B. (2022) In Journal of Asthma and Allergy 15. p.1491-1510
Abstract
Background: Many severe asthma patients with high oral corticosteroid exposure (HOCS) often do not initiate biologics despite being eligible. This study aimed to compare the characteristics of severe asthma patients with HOCS who did and did not initiate biologics. Methods: Baseline characteristics of patients with HOCS (long-term maintenance OCS therapy for at least 1 year, or ≥4 courses of steroid bursts in a year) from the International Severe Asthma Registry (ISAR; https://isaregistries.org/), who initiated or did not initiate biologics (anti-lgE, anti-IL5/5R or anti-IL4R), were described at the time of biologic initiation or registry enrolment. Statistical relationships were tested using Pearson's chi-squared tests for categorical... (More)
Background: Many severe asthma patients with high oral corticosteroid exposure (HOCS) often do not initiate biologics despite being eligible. This study aimed to compare the characteristics of severe asthma patients with HOCS who did and did not initiate biologics. Methods: Baseline characteristics of patients with HOCS (long-term maintenance OCS therapy for at least 1 year, or ≥4 courses of steroid bursts in a year) from the International Severe Asthma Registry (ISAR; https://isaregistries.org/), who initiated or did not initiate biologics (anti-lgE, anti-IL5/5R or anti-IL4R), were described at the time of biologic initiation or registry enrolment. Statistical relationships were tested using Pearson's chi-squared tests for categorical variables, and t-tests for continuous variables, adjusting for potential errors in multiple comparisons. Results: Between January 2015 and February 2021, we identified 1412 adult patients with severe asthma from 19 countries that met our inclusion criteria of HOCS, of whom 996 (70.5%) initiated a biologic and 416 (29.5%) did not. The frequency of biologic initiation varied across geographical regions. Those who initiated a biologic were more likely to have higher blood eosinophil count (483 vs 399 cells/µL, p=0.003), serious infections (49.0% vs 13.3%, p (Less)
Please use this url to cite or link to this publication:
author
; and
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Biologics, Patient characteristics, Real-world, Severe asthma, Treatment pattern
in
Journal of Asthma and Allergy
volume
15
pages
20 pages
publisher
Dove Medical Press Ltd
external identifiers
  • scopus:85141030684
  • pmid:36303891
ISSN
1178-6965
DOI
10.2147/JAA.S377174
language
English
LU publication?
yes
id
7b4824c6-4a6d-4978-8e2d-c05e1b596b5f
date added to LUP
2023-01-11 13:38:55
date last changed
2025-03-07 23:10:40
@article{7b4824c6-4a6d-4978-8e2d-c05e1b596b5f,
  abstract     = {{Background: Many severe asthma patients with high oral corticosteroid exposure (HOCS) often do not initiate biologics despite being eligible. This study aimed to compare the characteristics of severe asthma patients with HOCS who did and did not initiate biologics. Methods: Baseline characteristics of patients with HOCS (long-term maintenance OCS therapy for at least 1 year, or ≥4 courses of steroid bursts in a year) from the International Severe Asthma Registry (ISAR; https://isaregistries.org/), who initiated or did not initiate biologics (anti-lgE, anti-IL5/5R or anti-IL4R), were described at the time of biologic initiation or registry enrolment. Statistical relationships were tested using Pearson's chi-squared tests for categorical variables, and t-tests for continuous variables, adjusting for potential errors in multiple comparisons. Results: Between January 2015 and February 2021, we identified 1412 adult patients with severe asthma from 19 countries that met our inclusion criteria of HOCS, of whom 996 (70.5%) initiated a biologic and 416 (29.5%) did not. The frequency of biologic initiation varied across geographical regions. Those who initiated a biologic were more likely to have higher blood eosinophil count (483 vs 399 cells/µL, p=0.003), serious infections (49.0% vs 13.3%, p}},
  author       = {{Chen, W. and Bjermer, L. and Price, D.B.}},
  issn         = {{1178-6965}},
  keywords     = {{Biologics; Patient characteristics; Real-world; Severe asthma; Treatment pattern}},
  language     = {{eng}},
  pages        = {{1491--1510}},
  publisher    = {{Dove Medical Press Ltd}},
  series       = {{Journal of Asthma and Allergy}},
  title        = {{Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy}},
  url          = {{http://dx.doi.org/10.2147/JAA.S377174}},
  doi          = {{10.2147/JAA.S377174}},
  volume       = {{15}},
  year         = {{2022}},
}